Alzheimer's disease: Another target for heparin therapy

Luigi Bergamaschini, Emanuela Rossi, Carlo Vergani, Maria Grazia De Simoni

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is the leading cause of dementia and cognitive decline in the elderly. Brain tissue changes indicate that the two main proteins involved in AD are amyloid-beta (Aβ), which is associated with the formation of senile amyloid plaques, and tau, which is associated with the formation of neurofibrillary tangles. Although a central role for Aβ in the pathogenesis of AD is indisputable, considerable evidence indicates that Aβ production is not the sole culprit in AD pathology. AD is also accompanied by an inflammatory response that contributes to irreversible changes in neuronal viability and brain function, and accumulating evidence supports the pivotal role of complement and contact systems in its pathogenesis and progression. The complexity of AD pathology provides numerous potential targets for therapeutic interventions. Compounds that interact directly with Aβ protein or interfere with its production and/or aggregation can reduce the inflammatory and neurotoxic effects of Aβ, and heparin, a glycosaminoglycan mixture currently used in the prophylaxis and treatment of thrombosis, might be a candidate, as recent research has been extended to consider its nonanticoagulant properties, including its modulation of various proteases and anti-inflammatory activity.

Original languageEnglish
Pages (from-to)891-908
Number of pages18
JournalTheScientificWorldJournal
Volume9
DOIs
Publication statusPublished - Sep 1 2009

Fingerprint

Heparin
Alzheimer Disease
Amyloid Plaques
Pathology
pathology
Amyloid
brain
Brain
Therapeutics
Neurofibrillary Tangles
protein
Glycosaminoglycans
Dementia
therapy
viability
Proteins
Thrombosis
Peptide Hydrolases
Anti-Inflammatory Agents
Agglomeration

Keywords

  • Alzheimer's disease
  • Amyloid-beta
  • Complement system
  • Contact/kinin system
  • Heparin
  • Inflammation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Environmental Science(all)
  • Medicine(all)

Cite this

Alzheimer's disease : Another target for heparin therapy. / Bergamaschini, Luigi; Rossi, Emanuela; Vergani, Carlo; De Simoni, Maria Grazia.

In: TheScientificWorldJournal, Vol. 9, 01.09.2009, p. 891-908.

Research output: Contribution to journalArticle

Bergamaschini, Luigi ; Rossi, Emanuela ; Vergani, Carlo ; De Simoni, Maria Grazia. / Alzheimer's disease : Another target for heparin therapy. In: TheScientificWorldJournal. 2009 ; Vol. 9. pp. 891-908.
@article{06b251e124f84ba2898c276248a15845,
title = "Alzheimer's disease: Another target for heparin therapy",
abstract = "Alzheimer's disease (AD) is the leading cause of dementia and cognitive decline in the elderly. Brain tissue changes indicate that the two main proteins involved in AD are amyloid-beta (Aβ), which is associated with the formation of senile amyloid plaques, and tau, which is associated with the formation of neurofibrillary tangles. Although a central role for Aβ in the pathogenesis of AD is indisputable, considerable evidence indicates that Aβ production is not the sole culprit in AD pathology. AD is also accompanied by an inflammatory response that contributes to irreversible changes in neuronal viability and brain function, and accumulating evidence supports the pivotal role of complement and contact systems in its pathogenesis and progression. The complexity of AD pathology provides numerous potential targets for therapeutic interventions. Compounds that interact directly with Aβ protein or interfere with its production and/or aggregation can reduce the inflammatory and neurotoxic effects of Aβ, and heparin, a glycosaminoglycan mixture currently used in the prophylaxis and treatment of thrombosis, might be a candidate, as recent research has been extended to consider its nonanticoagulant properties, including its modulation of various proteases and anti-inflammatory activity.",
keywords = "Alzheimer's disease, Amyloid-beta, Complement system, Contact/kinin system, Heparin, Inflammation",
author = "Luigi Bergamaschini and Emanuela Rossi and Carlo Vergani and {De Simoni}, {Maria Grazia}",
year = "2009",
month = "9",
day = "1",
doi = "10.1100/tsw.2009.100",
language = "English",
volume = "9",
pages = "891--908",
journal = "The Scientific World Journal",
issn = "2356-6140",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Alzheimer's disease

T2 - Another target for heparin therapy

AU - Bergamaschini, Luigi

AU - Rossi, Emanuela

AU - Vergani, Carlo

AU - De Simoni, Maria Grazia

PY - 2009/9/1

Y1 - 2009/9/1

N2 - Alzheimer's disease (AD) is the leading cause of dementia and cognitive decline in the elderly. Brain tissue changes indicate that the two main proteins involved in AD are amyloid-beta (Aβ), which is associated with the formation of senile amyloid plaques, and tau, which is associated with the formation of neurofibrillary tangles. Although a central role for Aβ in the pathogenesis of AD is indisputable, considerable evidence indicates that Aβ production is not the sole culprit in AD pathology. AD is also accompanied by an inflammatory response that contributes to irreversible changes in neuronal viability and brain function, and accumulating evidence supports the pivotal role of complement and contact systems in its pathogenesis and progression. The complexity of AD pathology provides numerous potential targets for therapeutic interventions. Compounds that interact directly with Aβ protein or interfere with its production and/or aggregation can reduce the inflammatory and neurotoxic effects of Aβ, and heparin, a glycosaminoglycan mixture currently used in the prophylaxis and treatment of thrombosis, might be a candidate, as recent research has been extended to consider its nonanticoagulant properties, including its modulation of various proteases and anti-inflammatory activity.

AB - Alzheimer's disease (AD) is the leading cause of dementia and cognitive decline in the elderly. Brain tissue changes indicate that the two main proteins involved in AD are amyloid-beta (Aβ), which is associated with the formation of senile amyloid plaques, and tau, which is associated with the formation of neurofibrillary tangles. Although a central role for Aβ in the pathogenesis of AD is indisputable, considerable evidence indicates that Aβ production is not the sole culprit in AD pathology. AD is also accompanied by an inflammatory response that contributes to irreversible changes in neuronal viability and brain function, and accumulating evidence supports the pivotal role of complement and contact systems in its pathogenesis and progression. The complexity of AD pathology provides numerous potential targets for therapeutic interventions. Compounds that interact directly with Aβ protein or interfere with its production and/or aggregation can reduce the inflammatory and neurotoxic effects of Aβ, and heparin, a glycosaminoglycan mixture currently used in the prophylaxis and treatment of thrombosis, might be a candidate, as recent research has been extended to consider its nonanticoagulant properties, including its modulation of various proteases and anti-inflammatory activity.

KW - Alzheimer's disease

KW - Amyloid-beta

KW - Complement system

KW - Contact/kinin system

KW - Heparin

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=70350749549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350749549&partnerID=8YFLogxK

U2 - 10.1100/tsw.2009.100

DO - 10.1100/tsw.2009.100

M3 - Article

C2 - 19734963

AN - SCOPUS:70350749549

VL - 9

SP - 891

EP - 908

JO - The Scientific World Journal

JF - The Scientific World Journal

SN - 2356-6140

ER -